Other top stories

The History of Dopaminergic Blockade in Schizophrenia

October 4, 2024

Beyond Dopamine: Evaluating the Pipeline for Schizophrenia

October 4, 2024

Xanomeline-Trospium and Iclepertin Show Promise in Managing Cognitive Impairment in Schizophrenia

October 4, 2024

Schizophrenia’s Acute Psychosis Crisis Calls for Novel Treatments

October 4, 2024

A Third of Former NFL Players Believe They Have CTE

October 3, 2024

Xanomeline-Trospium Shows Promise in Schizophrenia with Fewer Side Effects

October 3, 2024

Other stories

Evaluating Pooled Data from the EMERGENT Study Programs

October 3, 2024

Study Links Conversion Therapy to Increased PTSD, Other Issues

October 2, 2024

Study Highlights Increased Mortality Risks in Difficult-to-Treat Depression

October 1, 2024

Study Finds Brain Network That Could Protect Against PTSD

September 30, 2024

Weekly Mind Reader: The Price of Social Isolation

September 27, 2024

FDA Approves First New Schizophrenia Drug in Years

September 27, 2024

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe